Regeneron Pharma posted fourth-quarter earnings and revenue that were above analysts' expectations on Friday.
Regeneron Pharma reported $23.72 earnings per share on $4.95 billion in revenue. Analysts who polled predicted EPS of $20.06 on revenue of $4.5 billion.
Regeneron Pharma's stock has dropped 1.71% since the start of the year, and it is still down 9.60% from its 52-week high of $686.62 set on September 3, 2021. They have outperformed the S&P 500, which has dropped 6.06% since the beginning of the year.
This month, Regeneron Pharma's profits will be followed by those of other large healthcare companies.
UnitedHealth announced earnings of $4.48 per share on revenue of $73.74 billion on January 19, beating estimates of $4.3 per share on revenue of $72.98 billion.
J&J surpassed forecasts on January 25 with EPS of $2.13 on revenue of $24.8 billion, vs a projection of $2.12 on revenue of $25.28 billion.
Visit Investing.com's earnings calendar to stay up to date on all forthcoming earnings reports.